HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote ()	6/27/2000 9:12:00 AM
From: nigel bates	of 1022

June 27 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) today announced the issuance of a second U.S. patent on its core technology. The new patent covers a method for producing a transgenic mouse capable of generating fully human antibodies. ``This patent demonstrates the fundamental contributions made by Abgenix scientists to the technology of generating fully human antibodies for use as therapies against human disease,'' stated R. Scott Greer, Chairman and CEO of Abgenix. ``XenoMouse technology has been described in eighteen papers written by Abgenix scientists and published in leading scientific publications.'' www.abgenix.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next